Neovacs Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Hugo Brugiere
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -€5m |
| Mar 31 2023 | n/a | n/a | -€4m |
| Dec 31 2022 | n/a | n/a | -€4m |
| Sep 30 2022 | n/a | n/a | -€8m |
| Jun 30 2022 | n/a | n/a | -€11m |
| Mar 31 2022 | n/a | n/a | -€12m |
| Dec 31 2021 | n/a | n/a | -€12m |
| Sep 30 2021 | n/a | n/a | -€7m |
| Jun 30 2021 | n/a | n/a | -€3m |
| Mar 31 2021 | n/a | n/a | -€5m |
| Dec 31 2020 | €85k | €75k | -€6m |
Compensation vs Market: Insufficient data to establish whether Hugo's total compensation is reasonable compared to companies of similar size in the German market.
Compensation vs Earnings: Insufficient data to compare Hugo's compensation with company performance.
CEO
Hugo Brugiere
no data
Tenure
€85,000
Compensation
Mr. Hugo Brugière, M. Sc., has been Director of Pharnext SA since November 2022 and serves as its Chairman and Chief Executive Officer since December 28, 2022. He has been Chief Executive Officer of Cyberg...